Alphyn Biologics Secures U.S. Patent for Atopic Dermatitis Drug

Alphyn Biologics Amplifies Innovation with New Patent

Patent covers active pharmaceutical ingredient ensuring long-term protection.

Alphyn Biologics, a clinical-stage dermatology company committed to developing innovative Multi-Target Therapeutics, has made a notable advancement. The United States Patent and Trademark Office (USPTO) has awarded Alphyn a patent for the active pharmaceutical ingredient (API) in its leading candidate aimed at treating atopic dermatitis (AD). This strengthens its growing research and development efforts in dermatological therapies.

CEO Neal Koller expressed enthusiasm over this achievement, stating, "This is a significant milestone for Alphyn. With our existing patent protecting Zabalafin Hydrogel, we now have extensive protection for our products’ composition and the methods for making and using them." This new patent not only enhances the company's intellectual property but also emphasizes its commitment to innovative solutions in dermatological care.

The patent obtained covers the topical application of Alphyn's drug raw material specifically targeting the treatment of atopic dermatitis, extending protection for a considerable duration until 2041. Furthermore, it complements their existing patent for Zabalafin Hydrogel, which carries a protection term until 2043. Upon receiving FDA approval for the AD drug, both patents will be eligible for listing in the FDA's Orange Book, providing added regulatory benefits.

Alphyn's patent portfolio is expanding rapidly, covering its various therapeutic agents and its unique Multi-Target Therapeutic Platform, with numerous applications already filed across different global jurisdictions. The company has also recently received a Notice of Allowance on a crucial patent for Zabalafin Hydrogel from the European Patent Office, demonstrating its global ambition.

About Alphyn Biologics

Alphyn Biologics, Inc. is dedicated to the development of first-in-class Multi-Target Therapeutics for widely prevalent and severe skin conditions, leveraging its innovative Zabalafin Platform. Their flagship product, Zabalafin Hydrogel, is already showing promising efficacy and safety results from Phase 2a clinical trials, positioning it as a potential first-line treatment for atopic dermatitis.

The Zabalafin Hydrogel formulation is distinctive for its ability to address the multifaceted challenges posed by AD, targeting not only the intense itching, but also the bacterial aspect and the immune-inflammatory response associated with this common skin condition. This holistic approach aims to provide a worry-free, long-term treatment option.

Alphyn's Zabalafin Platform features multiple bioactive compounds, unveiling a variety of mechanisms designed to ensure effective outcomes, boosting the pipeline for dermatological therapies while emphasizing safety and tolerability for patients. Since commencing operations in 2020, Alphyn has successfully built a solid operational base in Annapolis, Maryland, and Cincinnati, Ohio, along with wholly-owned subsidiaries in Australia and Austria, raising around $21 million to drive its research and development.

The company’s focus on details and innovative strategies indicates its readiness to navigate the complex regulatory landscape while offering compelling solutions for patients struggling with skin diseases.

Frequently Asked Questions

What recent patent did Alphyn Biologics receive?

Alphyn Biologics received a new U.S. patent covering the active pharmaceutical ingredient for its lead candidate targeting atopic dermatitis, ensuring protection until 2041.

What is the significance of the Zabalafin Hydrogel?

Zabalafin Hydrogel is a unique topical treatment for atopic dermatitis, directly addressing its symptoms and underlying causes, potentially revolutionizing AD care.

How does Alphyn Biologics protect its innovations?

Alphyn has built a robust patent portfolio, including patents for both its API and Zabalafin Hydrogel, providing extensive IP protection across multiple jurisdictions.

Where is Alphyn Biologics based?

Alphyn Biologics has operational bases in Annapolis, Maryland, and Cincinnati, Ohio, with additional subsidiaries in Australia and Austria.

How much funding has Alphyn Biologics raised?

Since its inception in 2020, Alphyn Biologics has raised approximately $21 million to support its research and development efforts.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.